IGES Pharma at BIO Japan 2024

IGES Pharma is taking part in the BIO Japan 2024 convention, the second largest industry event of its kind for the biopharmaceutical sector. The focus is on dialogue with innovative Asian biopharmaceutical companies on market access and reimbursement in Europe.

BIO Japan 2024 will take place in Yokohama from October 9 to 11. This event consists of three exhibitions: “Bio Japan”, which is the oldest biotechnology exhibition in the world (since 1986), “Regenerative Medicine JAPAN”, which aims to accelerate and industrialize research and development in the field of regenerative medicine, and “health TECH JAPAN”, which offers a fusion of digital technology and life sciences. IGES Pharma is taking part in the conference with experts from the life sciences sector. The aim is to engage in dialogue with researchers, companies and associations on international market access and reimbursement strategies for medical innovations.

The ongoing harmonization of health technology assessments (HTAs) in Europe, one of the most far-reaching changes in EU pharmaceutical legislation, will be an important topic in this year's discussions. As stakeholders, IGES Group companies were involved in the public consultations on the development of guidelines and guidance documents as part of the EUnetHTA21 activities.
IGES Pharma has been active in Asia for several years, where the biotechnological research landscape is producing significant innovations. In Japan, in particular, there is a remarkable biotech start-up scene with many promising drug candidates in late-stage clinical development. In addition, there exists a broad-based pharmaceutical industry with many large and medium-sized, globally successful companies.

The IGES Group as a whole offers a broad spectrum of research and consulting services for global developers and manufacturers of pharmaceuticals, medical devices and digital health applications. The services support almost all phases of product life cycle management for new developments. They are focused on the most important European healthcare markets.

Panel at BIO-EUROPE: Start early, seek advice, talk to the HTA Agencies
EU-HTA will start in time in 69 days. Fundamental implementing acts adopted – preparations under time pressure but will finish in time.
IGES Pharma at BIO Japan 2024
IGES Pharma is taking part in the BIO Japan 2024 convention, the second largest industry event of its kind for the biopharmaceutical sector. The focus is on dialogue with innovative Asian biopharmaceutical companies on market access and reimbursement in Europe.
Santoke Naal from IGES at the BIO 2024 International Convention: "It is important to engage much earlier with the HTA-Agencies than before.”
The panel “Europe's Policy Environment and the Impact on the Biotech Sector” analyzed the proposed revisions to the General Pharmaceutical Legislation (GPL) , including changes to regulatory data protection.
Expert discussion with IGES: Focus on transatlantic cooperation in the biotech sector
The world's largest biotech congress of its kind, the BIO International Convention, has a strong European focus this year. With the participation of the IGES Group, it brings together major European pharmaceutical and biotech stakeholders to discuss the latest changes in EU legislation and their consequences for the transatlantic pharmaceutical market. The congress will be held in San Diego, California, from 3 to 6 June. More than 20,000 visitors are expected to attend.
IGES Group with HTA experts at BIO-Europe Spring 2024
The IGES Group is once again taking part in BIO-Europe Spring, one of the largest trade fairs of its kind for the life sciences sector in Europe. The main focus will be on the exchange of information on the European Health Technology Assessment (HTA) procedure, EU-HTA.
Current documents on the EU-HTA process and opportunity to provide feedback
On March 5, 2024 the draft implementing regulation was published for public consultation on the “have your say” homepage of the EU – and is open for feedback for four weeks until 02 April 2024.
12 January 2025 - The Countdown runs
Pharmaceuticals and medical devices - the countdown runs! January 12, 2025, the era of national product assessments ends and the application of the EU HTA Regulation begins.
IGES Life Science at the health economics conference ISPOR Europe 2023
The IGES Group will once again be present at the European conference of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). The focus will be on the new, centralized HTA procedure, EU-HTA. As part of the scientific program, IGES experts will present current analyses on orphan drugs. ISPOR Europe 2023 will take place from November 12 to 15 in Copenhagen.
EU HTA harmonisation under time pressure: discussion at the biotech congress "BIO Europe 2023"
The time pressure due to EU HTA harmonisation is growing. In less than 15 months, the first medicinal products must undergo a central, EU-wide clinical evaluation procedure. The procedure itself is also taking place under high time pressure - with very tight deadlines and largely parallel to the marketing authorisation. What companies should urgently do now to successfully bring their new developments through the procedure is the topic of an IGES expert event at BIO Europe 2023 on 07 November in Munich.
IGES sets up a new subsidiary in France – IGES France Pharma Consulting
Continuation of its European growth course – Expansion of the services for pharmaceutical companies in Europe
IGES acquires majority stake in Synergus RWE – a European Medtech market access specialist
Continuation of its European growth course – Expansion of services for manufacturers of medical devices - Integration of the use of Scandinavian medical registries

Bringing Innovations to European Patients

IGES Pharma at BIO Japan 2024